Jerónimo Herrero Manso

BiatGroup, Biotechnology Assets, is a Biotech Corporate Group devoted to Discover, Develop and Bring to the Market Next-Generation Solutions for Global Health: from Smart Vaccines to tailor made Immunotherapy Tools.

BiatGroup, Biotechnology Assets, is a Biotech Corporate Group devoted to Discover, Develop and Bring to the Market Next-Generation Solutions for Global Health: from Smart Vaccines to tailor made Immunotherapy Tools.

IGEN BIOTECH GROUP is working in new approaches to Medicine, discovering a variety of biological activities from vegetal and animal sources, which entail a major potential in terms of therapy and preventive diagnosis. IGEN BIOLAB, as part of Igen Biotech Group works on the specific development of a functional protein profile for oncological and degenerative diseases. IGEN BIOLAB specializes in protein production, bacterial characterization and development of manufacturing processes that are optimized for robust high scale up production. Our R&D facilities include technical areas of In vitro cultivation and testing of microorganisms, mass spectrometry-based proteomics technologies to identify, characterize and quantify target proteins in various biological and biomedical samples, metabolomics for detection and quantification of small molecules (metabolites) in biological materials, microbiomics focusing on using molecular DNA microarray technology to address the complexities of human infections and environmental microbiome ecology. Our commitment is to develop functional protein immunotherapies that help physicians and other healthcare professionals to provide high quality medical nutrition care and to improve patients’ quality of life.

Patients suffering severe diseases, which often are life-threatening, are the focus of our efforts. This approach is the essential condition for the success of our work, in which not only our employees are involved, but also our partners and external collaborators. Our commitment to medical progress goes hand in hand with our commitment towards our patients: everyone who might benefit from our findings must have the opportunity to do so. This promise is extended to physicians and the community of all those involved in patient care. Functional protein immunotherapies help physicians and other healthcare professionals to provide high quality medical nutrition care and to improve patients’ quality of life. The staff at IGEN BIORESEARCH GROUP works every day in order to keep this promise. From our point of view, IGEN BIORESEARCH GROUPs portfolio developments represents a promise in itself. Not only does it represent an important potential for the company, but also new possibilities and new hopes for hundreds of thousands of people worldwide who are suffering oncologic and degenerative diseases. IGEN BIORESEARCH GROUP is working for them in terms of new approaches to Medicine, discovering a variety of biological activities from vegetal and animal sources, which entail a major potential in terms of therapy and preventive diagnosis.